Tide Point Capital Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Tide Point Capital Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-20,000	Closed	-$1.04M	–	49
2014 Q4	$1.04M	Buy	+20,000	New	+$895K	0.17%	35

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Tide Point Capital Management's JUNO Position: Q1 2015 in Review

Tide Point Capital Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2015, closing a stake of 20,000 shares — an estimated $1.04M sold.

Tide Point Capital Management first reported a position in JUNO in Q4 2014 and held it in 1 quarter. The position peaked at $1.04M in Q4 2014. 120 funds tracked by Wall St. Rank hold JUNO as of Q1 2015.

Tide Point Capital Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
Tide Point Capital Management sold 20,000 Juno Therapeutics, Inc. shares in Q1 2015, an estimated $1.04M.
Tide Point Capital Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
Tide Point Capital Management's Juno Therapeutics, Inc. position peaked at $1.04M in Q4 2014.
120 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2015.

Based on Tide Point Capital Management's 13F filing for Q1 2015, filed 15 May 2015.